Mifamurtide
An immune activator for osteosarcoma, approved in Europe but not the US
Mifamurtide is a synthetic muramyl tripeptide linked to a phospholipid and carried in liposomes. It activates macrophages to attack osteosarcoma cells, especially in the lungs. The EU authorised it as Mepact in 2009 for young people with non-metastatic osteosarcoma after surgery, given with chemotherapy; it is not approved in the US.
Used in human trials: 2 mg/m², Twice weekly, then weekly, Intravenous infusion (Study: recurrent or metastatic osteosarcoma (patient-access programme)) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Muramyl dipeptide is the smallest part of the bacterial cell wall that the immune system recognises. Mifamurtide is a synthetic relative, muramyl tripeptide, joined to a phospholipid and packaged in liposomes that macrophages take up, particularly in the lungs, where osteosarcoma tends to spread. It is not toxic to tumour cells itself; it works by turning macrophages against them.
A pivotal Children's Oncology Group trial led to its approval in Europe and, by one review's count, in over 40 countries. In that trial, Intergroup-0133, 662 patients with non-metastatic disease were randomised; adding the drug lifted six-year overall survival from 70% to 78%, while the improvement in event-free survival fell short of significance. The metastatic cohort showed the same pattern without reaching significance. Its short-term side effects are fever, headache, flu-like symptoms and rigors.
Not everyone reads that trial the same way. Prescrire, the French drug bulletin, called mifamurtide ineffective and harmful, arguing that the single trial was unblinded and complex and that adverse events were incompletely recorded. A 2017 systematic review found no event-free survival benefit but a survival benefit in non-metastatic disease. A European trial in metastatic or recurrent disease closed early with no responses.
More recent data are mixed in emphasis. In a merged Italian and Spanish analysis of 398 patients, where mifamurtide was added for tumours with high P-glycoprotein, event-free survival was better with mifamurtide plus chemotherapy, and a 2025 gene-signature study is exploring which patients respond. In the US it is not approved.
In healthy volunteers it clears from the blood within hours, with a burst of inflammatory cytokines that explains the fever and chills, and it did not change how children cleared high-dose methotrexate. Laboratory work suggests IL-10 may limit its effect.
Mechanism of Action
Mifamurtide is liposomal muramyl tripeptide phosphatidylethanolamine: a synthetic bacterial cell-wall fragment that activates macrophages against tumour cells.
Mimics bacteria
Muramyl peptides are recognised by the innate immune system as a sign of bacterial infection.
Macrophages switched on
Liposomes are taken up by macrophages, especially in the lungs, which then attack tumour cells; IL-6 and TNF-alpha rise within hours.
Short exposure
Serum half-life about 2 hours in healthy adults.
Published Research
Studies of mifamurtide, from their PubMed abstracts.
INT-0133: the pivotal trial
Among 662 patients with resectable, non-metastatic osteosarcoma randomised in a 2 x 2 design, adding muramyl tripeptide to chemotherapy raised 6-year overall survival from 70% to 78% (P = .03; hazard ratio 0.71); the gain in event-free survival was a trend only (P = .08).
Metastatic patients in the same trial
In the 91 patients with metastatic disease at diagnosis, 5-year event-free survival was 42% with liposomal MTP-PE and 26% without, and overall survival 53% against 40%; neither difference was statistically significant (P = .23 and .27).
Patient-access study in relapsed disease
205 patients with recurrent or metastatic osteosarcoma, given 2 mg/m2 twice weekly then weekly, had 3,679 infusion-related events over 7,482 infusions, very rarely grade 3 or 4; the half-life was 2 hours and 2-year survival 45.9%, uncontrolled.
Healthy volunteers: kinetics and heart rhythm
In 21 adults, MTP-PE had a serum half-life of about 2 hours; IL-6, TNF-alpha and CRP rose within hours and returned toward baseline by 8 hours. Heart rate rose without QTc prolongation; headache, chills and fever were common.
Methotrexate clearance unaffected
In 21 young patients with osteosarcoma, adding mifamurtide did not change the elimination of high-dose methotrexate.
A single-centre cohort
In 23 patients given mifamurtide with chemotherapy, compared with 26 historical controls, progression-free survival was better (landmark analysis p = 0.044); there were no dose-limiting toxicities.
Metastatic or recurrent disease: trial closed
A European phase 2 trial of mifamurtide alone or with ifosfamide in metastatic or recurrent osteosarcoma closed for poor recruitment, with no objective responses in the eight patients treated.
The pivotal result
Adding muramyl tripeptide (mifamurtide) to chemotherapy for osteosarcoma produced a trend towards improved event-free survival and a one-third reduction in the risk of death; it was approved in Europe for newly diagnosed osteosarcoma with chemotherapy.
Practical review
Mifamurtide is not cytotoxic in vitro but activates immune cells against lung metastases; adding it to chemotherapy improved 6-year overall survival by 8% in non-metastatic and 5-year by 13% in metastatic osteosarcoma, with fever, headache, flu-like symptoms and rigors as short-term toxicities.
From dogs to approval
Preclinical studies, including dogs with spontaneous osteosarcoma, showed that L-MTP-PE could control microscopic metastases, and a pivotal trial led to its approval in over 40 countries.
Italian and Spanish cohort
Among 398 patients, where mifamurtide was added for P-glycoprotein-positive tumours, 5-year event-free survival was superior with mifamurtide plus chemotherapy than with chemotherapy alone; overall 5-year survival was 74.8%.
Who responds
In 62 patients, a 21-gene immune signature separated high-risk (5-year survival 47%) from low-risk (92%) patients and is being explored to predict response to chemotherapy plus mifamurtide.
Systematic review
Across two studies and 802 patients, adding mifamurtide did not improve event-free survival but improved overall survival in non-metastatic disease and progression-free survival in metastatic or relapsed disease.
A critical view: Prescrire
Prescrire judged mifamurtide ineffective and harmful: one unblinded, complex trial, overall six-year survival about 75% either way by its reading, incomplete adverse-event recording, and reports of effusions, seizures and severe hearing loss.
IL-10 as the brake
In cell and animal experiments, blocking IL-10 alongside mifamurtide killed more high-grade osteosarcoma cells and reduced metastasis compared with mifamurtide alone.
Dosing Data
It is not approved in the US. In a large patient-access study it was given as an intravenous infusion of 2 mg/m² twice weekly, then weekly, alongside chemotherapy.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no regulator's label that says in what form Mifamurtide is supplied. It is prepared and given by clinical staff, not bought and mixed at home: the next part says where.
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Mifamurtide is prepared and given by clinical staff, by a cancer team in hospital.
In the carded studies it was infused into a vein, twice weekly then weekly, alongside chemotherapy for osteosarcoma.
Source: PMID 23997016 and PMID 18235123 (studies carded under Research below).
Storage before and after mixing
Unknown: no label on file says how Mifamurtide is stored. It is kept and prepared by the hospital or clinic that gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.
How it is taken
As it was given in human studies: Intravenous infusion (Twice weekly, then weekly; Study: recurrent or metastatic osteosarcoma (patient-access programme)).
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Study: recurrent or metastatic osteosarcoma (patient-access programme): Course of adjuvant therapy.
When effects appear: unknown; no source on this page gives a time to effect for Mifamurtide. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Fever, headache, flu-like symptoms and rigors, mostly short-term. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Mifamurtide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
- high-dose methotrexate: no significant change in methotrexate exposure (median AUC24-72 67.6 vs 84.5 umol*h/L, P = 0.61) in 11 children given mifamurtide; retrospective, 21 patients
Every peptide's record, with its source: the interaction matrix.
Source: human study, PMID 41999402.
Checking what you bought
Unknown: no published independent test of Mifamurtide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Not FDA Approved (Not approved by FDA). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No US label; it is not approved in the US.
Legal Status
Mifamurtide is authorised in the EU but not in the US.
Frequently Asked Questions
?Is mifamurtide a peptide?
It is a small peptide, muramyl tripeptide, chemically joined to a phospholipid and packaged in liposomes, so it is classed here as a peptide conjugate.
?Is Mepact approved in the US?
No. It is authorised in the EU for non-metastatic osteosarcoma after surgery, in combination with chemotherapy, but has no FDA approval.
?How much does it help?
Reviews of the pivotal trial describe a trend towards better event-free survival and about a one-third reduction in the risk of death when added to chemotherapy.
?Why is mifamurtide packaged in liposomes?
The liposomes contain phosphatidylserine, a signal macrophages respond to, so both the active drug and its carrier target immune cells in the lungs, where osteosarcoma most often spreads.
?Who is mifamurtide for?
In the EU, children, adolescents and young adults aged 2 to 30 at diagnosis with high-grade, resectable, non-metastatic osteosarcoma, after complete surgical removal, together with postoperative multi-agent chemotherapy.
References
- [regulator] European Medicines Agency, medicines register (download of October 3, 2026): Mepact (mifamurtide), authorised, marketing authorisation date 06/03/2009, indication as stated. https://www.ema.europa.eu/en/medicines/human/EPAR/mepact
- [pubmed] Meyers PA. "Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma." Expert Rev Anticancer Ther, 2009;9(8):1035-49. PMID: 19671023.
- [pubmed] Anderson PM, et al. "Mifamurtide in osteosarcoma--a practical review." Drugs Today (Barc), 2010;46(5):327-37. PMID: 20517534.
- [pubmed] Meyers PA. "Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma." Adv Exp Med Biol, 2020;1257:133-139. PMID: 32483736.
- [clinical-trial] Palmerini E, et al. "Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials." J Clin Oncol, 2025;43(28):3113-3122. PMID: 40825172.
- [pubmed] Palmerini E, et al. "Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial." Clin Cancer Res, 2025;31(18):3932-3943. PMID: 40711479.
- [clinical-trial] Meyers PA, et al. "Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group." J Clin Oncol, 2008;26(4):633-8. PMID: 18235123.
- [clinical-trial] Chou AJ, et al. "Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group." Cancer, 2009;115(22):5339-48. PMID: 19637348.
- [pubmed] Anderson PM, et al. "Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments." Pediatr Blood Cancer, 2014;61(2):238-44. PMID: 23997016.
- [pubmed] Venkatakrishnan K, et al. "A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers." Eur J Clin Pharmacol, 2012;68(10):1347-55. PMID: 22460239.
- [pubmed] Antebi M, et al. "Does mifamurtide affect the elimination of high-dose methotrexate in children with osteosarcoma?." Cancer Chemother Pharmacol, 2026;96(1). PMID: 41999402.
- [pubmed] Múdry P, et al. "Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - Observational prospective single institution analysis." J Bone Oncol, 2021;28:100362. PMID: 33948428.
- [pubmed] Barnes DJ, et al. "Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)." BMC Cancer, 2022;22(1):629. PMID: 35672690.
- [pubmed] Jimmy R, et al. "Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review." JBI Database System Rev Implement Rep, 2017;15(8):2113-2152. PMID: 28800058.
- [pubmed] "Mifamurtide: osteosarcoma: ineffective and harmful." Prescrire Int, 2011;20(115):89. PMID: 21648206.
- [pubmed] Nastasi N, et al. "Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma." Cancers (Basel), 2023;15(19). PMID: 37835437.
Sources & Citations
Studies were read from their PubMed abstracts; no US label exists. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.